NCT03140358

The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)

Active, enrolled Phase 3 Last updated 18 May 2025

What this trial tests

Phase 3 trial testing Atropine sulfate 0.01% in Myopia in 300 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

21 April 2017

Primary endpoint
31 December 2024

31 December 2025

Quick facts

Lead sponsor	Singapore National Eye Centre
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	300
Start date	21 April 2017
Primary completion	31 December 2024
Estimated completion	31 December 2025
Sites	1 location across Singapore

Drugs / interventions tested

• Atropine sulfate 0.01%
• Placebo

Conditions studied

• Myopia — all drugs for Myopia →

Sponsor

Singapore National Eye Centre — full company profile →

Who can join

Adults 5 to 9, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study of low dose atropine in preventing the onset and progression of myopia in high risk children with pre-myopia or low-myopia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. IMI 2021 Yearly Digest.
   Jong M, Jonas JB, Wolffsohn JS, Berntsen DA, et al · · 2021 · cited 59× · PMID 33909031 · DOI 10.1167/iovs.62.5.7
2. Efficacy and safety of interventions to control myopia progression in children: an overview of systematic reviews and meta-analyses.
   Prousali E, Haidich AB, Fontalis A, Ziakas N, et al · · 2019 · cited 45× · PMID 31072389 · DOI 10.1186/s12886-019-1112-3